Personalized briefing
Today’s briefing · Diabetes
Converging Evidence Reframes Cardiovascular-Kidney-Metabolic Risk Stratification
Dear Dr. Vijay Viswanathan, this is your personalized scientific intelligence briefing — curated for your work in Diabetes.
The connection
Three recent studies advance our understanding of cardiovascular risk in metabolic disease, each addressing distinct yet complementary mechanisms. At the molecular level, research on plasma exosome-derived miRNA-887-5p demonstrates that this microRNA can alleviate endothelial cell dysfunction induced by high glucose and lipids (Nutrition & Diabetes, 2026), offering a potential biomarker and therapeutic target for diabetic vascular complications. This finding gains clinical relevance when viewed alongside a large-scale analysis of the atherogenic index of plasma (AIP), which shows that novel adiposity-based composites of AIP provide modest but significant incremental prognostic information for all-cause and cardiovascular mortality in individuals with cardiovascular-kidney-metabolic (CKM) syndrome (Cardiovascular Diabetology, 2026).
Adding further nuance, a study on primary biliary cholangitis (PBC) with concurrent metabolic dysfunction-associated steatotic liver disease (MASLD) paradoxically reveals lower all-cause mortality and hepatic decompensation but significantly higher major adverse cardiovascular events (MACE) (Liver International, 2026). This suggests that the metabolic phenotype—characterized by adiposity and dyslipidemia—drives cardiovascular risk even when hepatic outcomes appear favorable. For the clinician managing patients with diabetes and its comorbidities, these findings underscore the need to integrate refined lipid indices and emerging molecular markers into routine risk assessment, moving beyond traditional metrics to capture the multifaceted nature of CKM risk.
References
Association of the atherogenic index of plasma and its integrative novel adiposity-based composites with all-cause and cardiovascular mortality in individuals with cardiovascular-kidney-metabolic syndrome: novel adiposity-derived AIP indices provide modest incremental prognostic information. (2026). Cardiovascular Diabetology. Read →
Hepatic and Cardiovascular Outcomes in Primary Biliary Cholangitis With Metabolic‐Dysfunction Associated Steatotic Liver Disease. (2026). Liver International, 46(8). Read →
Plasma exosome-derived miRNA-887-5p alleviates high glucose- and lipid-induced endothelial cell dysfunction. (2026). Nutrition & Diabetes. Read →
Advertisement
ScientificChina — The Global Marketplace for Scientific and Medical Equipments Start Browsing →
Your briefing is personalized based on your selected fields, keywords, and research interests.
